Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z. Guo Y, et al. Among authors: hong y. J Med Chem. 2019 Sep 12;62(17):7923-7940. doi: 10.1021/acs.jmedchem.9b00687. Epub 2019 Aug 19. J Med Chem. 2019. PMID: 31381333
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
Shi C, Wang Q, Liao X, Ge H, Huo G, Zhang L, Chen N, Zhai X, Hong Y, Wang L, Han Y, Xiao W, Wang Z, Shi W, Mao Y, Yu J, Xia G, Liu Y. Shi C, et al. Among authors: hong y. Eur J Med Chem. 2019 Sep 15;178:352-364. doi: 10.1016/j.ejmech.2019.06.005. Epub 2019 Jun 4. Eur J Med Chem. 2019. PMID: 31200237
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.
Jiang B, Zhang T, Deng M, Jin W, Hong Y, Chen X, Chen X, Wang J, Hou H, Gao Y, Gong W, Wang X, Li H, Zhou X, Feng Y, Zhang B, Jiang B, Lu X, Zhang L, Li Y, Song W, Sun H, Wang Z, Song X, Shen Z, Liu X, Li K, Wang L, Liu Y. Jiang B, et al. Among authors: hong y. Front Med. 2023 Dec;17(6):1170-1185. doi: 10.1007/s11684-023-0996-8. Epub 2023 Sep 25. Front Med. 2023. PMID: 37747585
Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
Liu J, Li S, Wang Q, Feng Y, Xing H, Yang X, Guo Y, Guo Y, Sun H, Liu X, Yang S, Mei Z, Zhu Y, Cheng Z, Chen S, Xu M, Zhang W, Wan N, Wang J, Ma Y, Zhang S, Luan X, Xu A, Li L, Wang H, Yang X, Hong Y, Xue H, Yuan X, Hu N, Song X, Wang Z, Liu X, Wang L, Liu Y. Liu J, et al. Among authors: hong y. Blood. 2024 May 2;143(18):1825-1836. doi: 10.1182/blood.2023019706. Blood. 2024. PMID: 38211332 Free PMC article.
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
Guo Y, Xue H, Hu N, Liu Y, Sun H, Yu D, Qin L, Shi G, Wang F, Xin L, Sun W, Zhang F, Song X, Li S, Wei Q, Guo Y, Li Y, Liu X, Chen S, Zhang T, Wu Y, Su D, Zhu Y, Xu A, Xu H, Yang S, Zheng Z, Liu J, Yang X, Yuan X, Hong Y, Sun X, Guo Y, Zhou C, Liu X, Wang L, Wang Z. Guo Y, et al. Among authors: hong y. J Med Chem. 2024 May 2. doi: 10.1021/acs.jmedchem.4c00027. Online ahead of print. J Med Chem. 2024. PMID: 38695063
12,255 results
You have reached the last available page of results. Please see the User Guide for more information.